ASPX Stock News 15.92 05/13/2014 16:30:40 Auspex Pharmaceuticals

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Auspex Pharmaceuticals Inc. (ASPX) 15.92 $ASPX

Auspex Pharmaceuticals Reports 2014 First Quarter Results
GlobeNewswire - 1 hr 29 mins ago
Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, today announced its financial results for the first quarter ended March 31, 2014.

Acute Coronary Syndrome - Pipeline Review, H1 2014: 21 Companies and 29 Drugs Profiled
M2 - Wed May 07, 12:15PM CDT
Research and Markets (http://www.researchandmarkets.com/research/2f56rx/acute_coronary) has announced the addition of the "Acute Coronary Syndrome - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Coronary Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development - Ampio Pharmaceuticals, Inc. - Arena Pharmaceuticals, Inc. - Artery Therapeutics, Inc. - AstraZeneca PLC - Auspex Pharmaceuticals, Inc. - Bayer AG - CSL Limited - GlaxoSmithKline plc - LG Life Sciences, Ltd. - Lacer, S.A. - Lee's Pharmaceutical Holdings Limited - Ligand Pharmaceuticals, Inc. - MedImmune, LLC - Medicure Inc. - Pfizer Inc. - Regado Biosciences, Inc. - Stealth Peptides Inc. - The Medicines Company - Viron Therapeutics, Inc. - Vitae Pharmaceuticals, Inc. - XOMA Corporation Drug Profiles: - cangrelor - rivaroxaban - BAY-818781 - REG-1 - clopidogrel bisulfate - VT-111a - CSL-112 - gevokizumab - losmapimod - MTP-131 - ZK-001 - PR-15 - temanogrel hydrochloride - MDCO-216 - losmapimod - LC-231306 - ACP-501 - PF-06282999 - Artpep-2 - DMI-4983 - LA-8045 - COR-3 - COR-2 - AEM-28 - Type 5 Adenylyl Cyclase Inhibitors - tirofiban hydrochloride transdermal - Liver X Receptor Modulator For Acute Coronary Syndrome - Anti Platelet Program - SD-970 For more information visit http://www.researchandmarkets.com/research/2f...e_coronary

Huntington's Disease - Pipeline Review, H1 2014: 50 Company and 93 Drug Profiles
M2 - Wed May 07, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v2bgc4/huntingtons) has announced the addition of the "Huntington's Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Huntington's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Huntington's Disease and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - GAcadia Pharmaceuticals Inc. - Accera, Inc. - Alnylam Pharmaceuticals, Inc. - Angita B.V. - Aniona ApS - Auspex Pharmaceuticals, Inc. - Azevan Pharmaceuticals, Inc. - BioCrea GmbH - Centre de Regulacio Genomica - Chronos Therapeutics Limited - Cortex Pharmaceuticals, Inc. - CrystalGenomics, Inc. - EncephRx, Inc. - Evotec AG - GW Pharmaceuticals plc - Galenea Corp. - Suven Life Sciences Ltd. - Teva Pharmaceutical Industries Limited - Treventis Corporation - Trophos SA - UniQure BV - Valens Therapeutics, Inc. - Varinel, Inc. - Vertex Pharmaceuticals Incorporated - VivaCell Biotechnology Espana S.L. - Vybion, Inc. - Wellstat Therapeutics Corporation - enzyme Corporation - iPierian, Inc Drug Profiles: - pridopidine - SD-809 ER - Coenzyme Q10 - cysteamine DR - PF-02545920 - nabiximols - selisistat - PBT-2 - Epigallocatechin Gallate - BN-82451 - SOM-3355 - OMS-824 - SRX-251 - SRX-246 - SUVN-502 - GSK-356278 - uridine triacetate - Lithium citrate - ALN-HTT - CERE-120 - INDUS-815C - AC-0523 - Xpro-1595 - AN-726 - CX-929 - VAR-10300 - AMT-090 - noscapine - NsG-33 - MTP-131 For more information visit http://www.researchandmarkets.com/research/v2...untingtons

Auspex Pharmaceuticals Appoints Industry Veterans Lynn Bleil And Scott Greer To Its Board Of Directors
PR Newswire - Wed May 07, 7:00AM CDT
Auspex Pharmaceuticals, Inc. (Nasdaq: ASPX), a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, today announced the expansion of its Board of Directors with the appointment of two new members:

Auspex (ASPX) is now in Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon May 05, 7:51AM CDT
Auspex (ASPX) is now in Oversold Territory

Global Tourette Syndrome Therapeutic Pipeline Review 2014
M2 - Tue Apr 15, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/78vx5h/tourette_syndrome) has announced the addition of the "Tourette Syndrome - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Tourette Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tourette Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Tourette Syndrome - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Tourette Syndrome and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Tourette Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Tourette Syndrome pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Tourette Syndrome - Companies Involved in Therapeutics Development - AstraZeneca PLC - Neurocrine Biosciences, Inc. - NeuroSearch A/S - Catalyst Pharmaceutical Partners, Inc. - Auspex Pharmaceuticals, Inc. - Edison Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Psyadon Pharmaceuticals, Inc. Drug Profiles - aripiprazole - ecopipam hydrochloride - AZD-5213 - acetylcysteine - vigabatrin - valbenazine - seridopidine - vatiquinone - RP-5063 - SD-809 ER For more information visit http://www.researchandmarkets.com/research/78...e_syndrome

2 Stocks Spiking on Unusual Volume
at The Street - Mon Apr 07, 8:31AM CDT
Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

3 Notable Upcoming IPOs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 8:57AM CDT
The first three months of 2014 have been very productive for Initial Public Offerings. Here are a few more to consider.

Auspex Pharmaceuticals Added To The Russell 2000® Index
PR Newswire - Mon Mar 31, 3:57PM CDT
Auspex Pharmaceuticals, Inc. (Nasdaq: ASPX), a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, today announced that the Company was added to the Russell 2000® Index (as well as the larger Russell 3000® Index) at the close of market on March 31, 2014 as part of the quarterly Initial Public Offering (IPO) update to the Russell indexes.

Auspex Pharmaceuticals Reports 2013 Fourth Quarter And Full Year 2013 Financial Results
PR Newswire - Thu Mar 27, 3:19PM CDT
Auspex Pharmaceuticals, Inc. (Nasdaq: ASPX), a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, today announced its financial results for the fourth quarter and year ended December 31, 2013.

The NASDAQ Stock Market Leads U.S. Exchanges for IPOs in Q1 2014
GlobeNewswire - Thu Mar 27, 7:50AM CDT
74 New U.S. Listings Including 45 IPOs

Auspex Announces The Issuance Of Patents On Deuterium-Containing Form Of Pirfenidone (SD-560)
PR Newswire - Tue Mar 25, 3:01PM CDT
Auspex Pharmaceuticals, Inc. (Nasdaq: ASPX), a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, today announced the issuance of the following composition of matter and method of treatment patents covering its deuterium-containing form of pirfenidone (SD-560) drug candidate being developed for the potential treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic conditions:

Auspex To Present at BioCentury's Future Leaders in the Biotech Industry Conference
PR Newswire - Mon Mar 24, 7:00AM CDT
Auspex Pharmaceuticals, Inc. (Nasdaq: ASPX), a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, today announced that the company will present at BioCentury's Future Leaders in the Biotech Industry conference. The presentation will be delivered by Pratik Shah, Ph.D., President and CEO of Auspex Pharmaceuticals, at 10:30 a.m. EDT on Friday March 28th at the Millennium Broadway Hotel & Conference Center in New York.

Auspex Announces Completion Of Initial Public Offering And Exercise In Full Of Underwriters' Over-Allotment Option
PR Newswire - Mon Feb 10, 3:00PM CST
Auspex Pharmaceuticals, Inc. (Nasdaq: ASPX), a biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, today announced the completion of its initial public offering of 8,050,000 shares of its common stock at an initial public offering price of $12.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 1,050,000 additional shares of common stock. Auspex's common stock is listed on the NASDAQ Global Market under the trading symbol "ASPX." Auspex expects to use the net proceeds from the offering primarily for the clinical development and commercialization of SD-809, as well as for general corporate purposes.

Auspex prices IPO at USD12.00 per share
M2 - Wed Feb 05, 8:07AM CST
Auspex Pharmaceuticals Inc (Nasdaq:ASPX), a biopharmaceutical company focused on developing and commercialising novel medicines for the treatment of orphan diseases, announced today that it has priced an initial public offering of 7,000,000 shares of its common stock at a public offering price of USD12.00 per share.

Auspex Announces Pricing Of Initial Public Offering
PR Newswire - Tue Feb 04, 11:07PM CST
Auspex Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, today announced the pricing of its initial public offering of 7,000,000 shares of its common stock at a public offering price of $12.00 per share. Auspex has granted the underwriters a 30-day option to purchase up to an aggregate of 1,050,000 additional shares of common stock at the initial public offering price to cover any over-allotments. The shares are expected to begin trading on the NASDAQ Global Market, beginning on February 5, 2014, under the symbol "ASPX." The offering is expected to close on February 10, 2014, subject to customary closing conditions.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lennar Faces Legal Heat Over Alleged Misleading Statements

Updated Category News Views 78

Rumbling Legal Drama with Lennar Corporation Every trader knows the uneasy feeling when a stock you're eyeing takes a surprising nosedive on some legal muck coming out of the woodwork. Well, it's Lennar Corporation's turn in the spotlight for all the wrong reasons. They're getting slapped with a class action lawsuit by investors claiming the company pulled a fast one...

Continue Reading
Stephanie L. Beiermann Shines in HR Consulting Honors

Updated Category News Views 54

Celebrating a Star in Payroll Optimization Ah, the name Stephanie L. Beiermann’s been making the rounds lately, catching eyes with her lauded expertise in payroll optimization and human resources. This recognition doesn’t come out of thin air—no, it’s anchored on a solid foundation of over 25 years of cutting through the fluff to sharpen operational edges. We’re...

Continue Reading
Tackling the Industrialized Beast of Insurance Fraud

Updated Category News Views 27

Stepping Up the Fraud Fight This year's emerging fraud trends are taking the term 'organized crime' to new heights, and it's painting a bullseye on the insurance industry. The National Insurance Crime Bureau (NICB) just laid out how fraud isn't just a series of isolated scams anymore—it's an industrial-scale racket. As they spotlight during International Fraud Awareness...

Continue Reading
Keiki Smiles Boosts Pediatric Dental Care in Waipahu

Updated Category News Views 107

A Neighborhood Dentists' Big Move: Keiki Smiles Expands in Waipahu Well, if there's one thing the dentists of Waipahu know how to do, it's adapt and grow. Keiki Smiles of Leeward, a trusted name in pediatric dentistry, just set up shop at a fresh location. The move marks a new chapter for this community staple, and honestly, it's miles more than just a longer lease and a...

Continue Reading
Dar Global Expands Jeddah Portfolio with $267M Project

Updated Category News Views 190

Dar Global's Big Jeddah Move: A $267M Bet Alright, let's dive into what Dar Global's been up to in Saudi Arabia. They've just announced a whopping SAR 1 billion development project in Jeddah, bringing an international luxury brand to the city with an exclusive co-branded residential concept. Now that's something to chew on for any investor eyeing the Middle East's real...

Continue Reading
Apotex Enters U.S. Market with Axitinib Tablets Launch

Updated Category News Views 64

Apotex's Bold Move: Axitinib Tablets Hit the U.S. Market Apotex is shaking things up in the pharma world by launching the first generic version of Axitinib Tablets in the U.S., aimed at treating advanced renal cell carcinoma (RCC) when previous treatments have fallen flat. This isn't just another dance with the red tape—it's a major step for Apotex, flexing their muscle...

Continue Reading
Tuya Smart: AI Powers New Energy Wave at COP31

Updated Category News Views 119

Tuya Smart's Bold Move at COP31 Tuya Smart, a name you don't want to ignore in the world of energy innovation, made a commanding appearance at COP31. Their message was loud and clear: as the climate gets harsher, they're not just sitting around waiting for the next storm. They're arming households with AI-driven solutions. AI-Powered Energy Management Takes Center Stage...

Continue Reading
VIO Med Spa’s Black Friday Event: Aesthetic Savings

Updated Category News Views 152

Kicking Off the Holiday Season with a Glow Just when you think the holiday hustle can't get busier, VIO Med Spa is opening the gates of rejuvenation just in time to add yourself to that epic list. Starting November 16, VIO launches its Black Friday extravaganza—a deal-laden kick-off that means smooth skin and sharper looks are up for grabs. Member Benefits and Public...

Continue Reading
GALC Launches Tender Offer on 2027 Notes Amid Debt Play

Updated Category News Views 41

Aviation Leasing Giant's Strategic Financial Move Well folks, we're staring down the barrel of a financial maneuver by Global Aircraft Leasing Co., Ltd. (GALC) that’s not just another day at the office. They've kicked off a cash tender offer for their 8.750% Senior Secured Notes due 2027, aiming to sweep up any and all outstanding ones. That's $932 million in principle...

Continue Reading
Panasonic Showcases Rugged Tech at NATO Edge 26

Updated Category News Views 56

Panasonic Heads to Turkey with Tactical Tech Panasonic's got its sights set on proving a point at NATO Edge 26, busting out its TOUGHBOOK line and showing just how these rugged laptops aren't just tough, but also strategically essential. From November 17th through 19th, down in Turkey, these devices are taking the spotlight as they embrace the operational challenges of...

Continue Reading

Top 5 Most Recently Viewed Articles

Legacy of Lovers Unveils Transformative Single Addition

Updated Category News Views 154

Legacy of Lovers Launches New Musical Journey with 'Calm Cool Connection' With an exciting new release, Endless Love embraces the future of music with their single 'Calm Cool Connection'. This dynamic piece captures the essence of personal transformation and encourages listeners to embrace their own journeys. The track stands out, infused with bright melodies and...

Continue Reading
Major Shareholding Update for Park Street A/S Shareholders

Updated Category News Views 162

Significant Shareholding Announcement Park Street A/S is making headlines with its recent announcement regarding major shareholder developments. The company, a key player in its industry, has disclosed essential updates about the share capital and voting rights held by Park Street Asset Management Ltd., a trusted partner in managing its shareholding. Capital Reduction and...

Continue Reading
Alamos Gold's Robust Quarterly Dividend and Strategic Buybacks

Updated Category News Views 150

Quarterly Dividend Announcement by Alamos Gold All figures mentioned are in United States dollars unless specified otherwise. In a recent announcement, Alamos Gold Inc. (TSX:AGI; NYSE:AGI) has revealed a significant update regarding its shareholder value strategies. The Company’s Board of Directors has declared a quarterly dividend of US$0.025 per common share. This...

Continue Reading
AITX Expands Innovative Logistics Solutions with ROAMEO

Updated Category News Views 98

Revolutionizing Logistics with AITX and ROAMEO In an ever-changing world of logistics, AITX’s Robotic Assistance Devices, Inc. (RAD) is stepping up to the plate with new solutions that elevate operational efficiency and security standards. The company has honed its focus on creating tailored solutions for the logistics sector, which is widely acknowledged for its...

Continue Reading
BlackRock's Bold Bet on Bitcoin Amid Microsoft's Hesitation

Updated Category News Views 131

BlackRock's Investment Insights Into Bitcoin Microsoft Corp. (NASDAQ: MSFT) recently made headlines when it decided against exploring Bitcoin as a potential investment. Despite this, its significant shareholder, BlackRock, is making waves with its strong backing for the leading cryptocurrency. Known for its strategic investments, BlackRock's optimism presents a stark...

Continue Reading